{"organizations": [], "uuid": "b300eab336ba4dcdc5ed383a23d74d79317695e4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180430.html", "section_title": "Archive News &amp; Video for Monday, 30 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-edge-therapeutics-announces-review/brief-edge-therapeutics-announces-review-of-strategic-alternatives-idUSASC09Y6C", "country": "US", "domain_rank": 408, "title": "BRIEF-Edge Therapeutics Announces Review Of Strategic Alternatives", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.067, "site_type": "news", "published": "2018-04-30T19:10:00.000+03:00", "replies_count": 0, "uuid": "b300eab336ba4dcdc5ed383a23d74d79317695e4"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-edge-therapeutics-announces-review/brief-edge-therapeutics-announces-review-of-strategic-alternatives-idUSASC09Y6C", "ord_in_thread": 0, "title": "BRIEF-Edge Therapeutics Announces Review Of Strategic Alternatives", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "edge therapeutics inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "therapeutics inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 30 (Reuters) - Edge Therapeutics Inc:\n* EDGE THERAPEUTICS ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES\n* EDGE THERAPEUTICS INC - BOARD OF DIRECTORS IS CONDUCTING A COMPREHENSIVE REVIEW OF STRATEGIC ALTERNATIVES FOCUSED ON MAXIMIZING STOCKHOLDER VALUE\n* EDGE THERAPEUTICS INC - EDGE INTENDS TO STREAMLINE ITS OPERATIONS IN ORDER TO PRESERVE ITS CASH RESOURCES\n* EDGE THERAPEUTICS INC - HAS RETAINED PIPER JAFFRAY & CO. TO ACT AS ITS FINANCIAL ADVISOR TO ASSIST WITH REVIEW PROCESS\n* EDGE THERAPEUTICS INC - POTENTIAL STRATEGIC ALTERNATIVES THAT MAY BE EXPLORED/EVALUATED AS PART OF REVIEW INCLUDE ACQUISITION, MERGER Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-30T19:10:00.000+03:00", "crawled": "2018-05-01T19:52:51.001+03:00", "highlightTitle": ""}